Index

Note: Page numbers in italics refer to figures, those in bold refer to tables.

abciximab 52, 53
acute coronary syndrome 41, 42, 70
non-STEMI acute coronary syndrome 53
percutaneous coronary intervention adjacent 54
ablative therapy for atrial fibrillation/atrial flutter 80
acute coronary syndrome abciximab 41, 42, 70
aspiration catheters 42
‘conservative’ treatment 36
diagnosis 35
epidemiology 35
glycoprotein IIb/IIIa inhibitors 36, 37, 41, 53, 70
high-risk patients 36–7
‘invasive’ treatment 36
management 35–7
medical treatment 36, 41–2
non-STEMI 34–8
pathogenesis 34–5
recanalisation 39–40
STEMI 39–42
TIMI risk score 37
unstable angina 34–8
acute vessel closure, percutaneous coronary intervention 15
β-adrenoceptor blocking drugs 5, 87
age, risk factor increase 1
AH interval 72
airport security, pacemakers 86
aldosterone antagonists 87
Amplatzer occluder device 60, 95–6, 97
atrial septal defect device 96, 98
patent ductus arteriosus plug 96–7, 98
ventricular septal defect 97, 98
angina chronic stable 28–32
clinical risk assessment 19–20
coronary artery bypass graft comparison with medical treatment 29–30
diabetes mellitus 31–2
left main stem disease 32
medical treatment 19, 28–9
mortality 28
multivessel disease 31
percutaneous coronary intervention 28, 29, 30, 30–2, 53, 64, 66
refractory disease 32, 50
risk factor reduction 19
risk factors 28
single-vessel disease 30–1
treatment 28–52, 33
classification 14, 19
coronary artery bypass graft 5
exercise stress testing 8
management algorithm 7
stents 67
unstable 7
diagnosis 35
epidemiology 35
management 35–7
pathogenesis 34–5
angioplasty 94
see also percutaneous transluminal angioplasty (PTCA)
angioscopy 15
AngioSculpt balloon 68, 69
angiotensin-converting enzyme (ACE) inhibitors 3, 87
angiotensin II receptor blockers 87
anti-tachycardia pacing 77–8
atrioventricular conduction 71–2
duality of nodal 74
atrioventricular node compact 74
atrial tachyarrhythmias 60
atrial fibrillation 74–5, 80
atrial flutter 74, 80
atrial septal defect balloon mitral valveplasty 56
Biostar device 96
closure 60
occlusion device 96, 98
atrial tachyarrhythmias 80
atrioventricular conduction 71–2
duality of nodal 74
atrioventricular node compact 74
trokoype conducta 72–3
balloon angioplasty 15
balloon atrial septostomy 93, 94
balloon catheter, cutting 25
balloon dilatation, paediatric 93–4
balloon mitral valveplasty 93–4
balloon valvuloplasty 93–4
beta-blockers see β-adrenoceptor blocking drugs
bifurcation lesions 64, 66
Biostar atrial septal defect device 96
bicuradin 41, 51
blood pressure, support in cardiogenic shock 45, 46, 47
body mass index 1
blood pressure
pacemakers 81–6
pacing indications 83–4
broad QRS complex 80
burns 16
C-reactive protein, high-sensitivity (hs-CRP)
Canadian Cardiovascular Society, angina classification 14
cangrelor 52
cardiac magnetic resonance (CMR) 3, 9, 10
cardiac multidector computed tomography (MDCT) 9, 11
cardiac rehabilitation programmes 3
cardiac resynchronisation therapy (CRT) 86–9
defibrillator 89
NICE guidelines 91

COPYRIGHTED MATERIAL
risk factors (continued)
impact 2–3
modifying to improve prognosis 1–5
Sapien valve 57
septal ablation, ethanol 58–9
septal defect closure 60–1
sex-se certain activity, pacemakers 86
sick sinus syndrome 83
septostomy 93, 94
single photon emission tomography (SPECT), MUGA scan 9
sinus bradycardia 83
sinus rhythm 80, 91
smoking 2
social class 3
statins 4
stents 16–18
angina 67
balloon-mounted 20, 21
bifurcation 64, 66
covered 66, 95
current practice 17–18
drug-eluting 18, 23, 25, 226
chronic total occlusion 67
restenosis 26, 69
core problems 17
geometry 69
healing course 25
indicators for use 19
intra-operative pulmonary artery 98
materials 69
paediatric patients 94–5
percutaneous coronary intervention 69
perioperative patient care 24
primary percutaneous coronary intervention 41
pulmonary artery 95, 98
recanalisation 39, 40
restenosis 21–3, 25, 33–4
drug-eluting 26, 69
self-expanding 95
suboptimal expansion 17
stress echocardiography 8
supraventricular tachycardias 73–4
accessory pathways 73
paroxysmal 73–4
systolic dysfunction 87, 88
T-wave, intrinsic 81
target lesion revascularisation (TLR) 22–3
taxol, Dior drug-eluting balloon 68, 69
tinstitutome levels 3
tetralogy of Fallot 93
thienopyridines 52
thrombolytics 46, 47
myocardial infarction 46
thrombolytic agents 46, 47
recanalisation 39, 40
thrombus 23–4
stents 17
thrombus
embolisation of platelet-rich 35
formation 7, 49
non-STMI 34
STEMI 34
unstable angina 34
tacrolimus 52, 69–70
taxol 52
tiered therapy 77–8
TIMI risk score 37
tacrolimus 42, 52–3
percutaneous coronary intervention adjunct 34
STMI 53
tissue Doppler imaging 89, 90
transcatheter aortic valve implantation (TAVI) 57–8
travelling, pacemakers 86
triglycerides 1, 548
twiddler’s syndrome 85
unfractionated heparin 50–1, 52
acute coronary syndrome 36, 41
percutaneous coronary intervention adjunct 34
vein grafts, diseased 64, 66
ventricular arrhythmias 80
ventricular assist devices 45, 47
ventricular septal defect 45
congenital 61
occlusion devices 97, 98
periventricular closure 98
ventricular tachycardias 73–6
pacing termination 77–9
waist circumference 2, 3
warfarin, patent foramen ovale prevention 60
Wolff–Parkinson–White syndrome 72, 73